Controlled substance solutions

Start adding items to your reading lists:
Save this item to:
This item has been saved to your reading list.

Opioids are now the leading cause of accidental death in the United States, above car crashes and guns.1

$1.9B is a low estimate of annual hospital attributable to patients with opioid overdose between October 2017 and October 2018.2

1. National Safety Council, 2017. Injury Facts, 2017 Edition
2. Premier Inc. Analysis, Jan 2019

Tackling the opioid crisis

While the challenges are complex, healthcare providers and payers have the data necessary to provide a fact base of prescribing practices and potential drug diversion. They can use this to approach the problem in a multifaceted way that can potentially both mitigate risk and lower long-term costs.

PwC’s Controlled Substance Solutions deliver an understanding of your current state, a baseline of information to help you take action to tackle these issues and a process for monitoring progress.

How it works

1: Gain visibility

We provide ongoing visibility into provider prescribing practices and potential drug diversion.

2: Start the conversation

This can spark necessary conversations about enhanced standards of care and strategic initiatives in line with your social and regulatory responsibilities and risk tolerance.

3: Use analytics

This lays the foundation for you to begin using predictive analytics to help identify and engage those most at risk.

Related services

Diversion audits and analytics

Data that's useful in detecting potential diversion sits across multiple systems, including EHRs, resource scheduling apps, time cards, drug dispensing systems and physical access control systems. Brought together, new insights can be unlocked.

Compliance program assessments

Regulatory requirements are changing quickly and vary across local, state and federal agencies. Understanding them is the first step, and using your data to monitor compliance should be the next.

Financial Impact Assessments

Detecting and treating substance use disorder can improve a patient's health while reducing overall cost of care. New legislation and regulations are requiring more from providers, but they are also creating new opportunities.

Contact us

Ryan Martin

Ryan Martin

Partner, Risk and Regulatory, PwC US

Wayne Lombardi

Wayne Lombardi

Principal, Assurance, PwC US

Fran  Grabowski, Jr.

Fran Grabowski, Jr.

Director, Risk and Regulatory, PwC US

Russell Harder

Russell Harder

Partner, Risk and Regulatory, PwC US

Follow us